Univariate and bivariate analysis of factors associated with CMV disease
| Univariate . | . | . | . | . | . |
|---|---|---|---|---|---|
| Covariate . | Number of patients . | Number of events . | Category . | HR (95% CI) . | P . |
| CMV disease by d 100 | |||||
| GVHD prophylaxis | 322 | 11 | MTX | 1 | |
| 414 | 18 | MMF | 1.28 (0.60-2.70) | .525 | |
| 44 | 4 | PTCy | 2.70 (0.87-8.38) | .086 | |
| Donor relationship | 320 | 10 | Sibling | 1 | |
| 460 | 23 | Unrelated | 1.62 (0.77-3.40) | .2 | |
| Donor CMV serostatus | 408 | 24 | − | 1 | |
| 372 | 9 | + | 0.40 (0.19-0.87) | .02 | |
| Conditioning regimen | 379 | 16 | Nonmyeloablative/RIC | 1 | |
| 401 | 17 | Myeloablative | 1.01 (0.51-1.99) | .988 | |
| CMV disease by 1 y | |||||
| GVHD prophylaxis | 322 | 16 | MTX | 1 | |
| 414 | 31 | MMF | 1.52 (0.83-2.78) | .175 | |
| 44 | 4 | PTCy | 1.88 (0.63-5.66) | .261 | |
| Donor relationship | 320 | 15 | Sibling | 1 | |
| 460 | 36 | Unrelated | 1.70 (0.93-3.10) | .083 | |
| Donor CMV serostatus | 408 | 33 | − | 1 | |
| 372 | 18 | + | 0.58 (0.33-1.03) | .065 | |
| Conditioning regimen | 379 | 26 | Nonmyeloablative/RIC | 1 | |
| 401 | 25 | Myeloablative | 0.91 (0.53-1.57) | .733 | |
| Univariate . | . | . | . | . | . |
|---|---|---|---|---|---|
| Covariate . | Number of patients . | Number of events . | Category . | HR (95% CI) . | P . |
| CMV disease by d 100 | |||||
| GVHD prophylaxis | 322 | 11 | MTX | 1 | |
| 414 | 18 | MMF | 1.28 (0.60-2.70) | .525 | |
| 44 | 4 | PTCy | 2.70 (0.87-8.38) | .086 | |
| Donor relationship | 320 | 10 | Sibling | 1 | |
| 460 | 23 | Unrelated | 1.62 (0.77-3.40) | .2 | |
| Donor CMV serostatus | 408 | 24 | − | 1 | |
| 372 | 9 | + | 0.40 (0.19-0.87) | .02 | |
| Conditioning regimen | 379 | 16 | Nonmyeloablative/RIC | 1 | |
| 401 | 17 | Myeloablative | 1.01 (0.51-1.99) | .988 | |
| CMV disease by 1 y | |||||
| GVHD prophylaxis | 322 | 16 | MTX | 1 | |
| 414 | 31 | MMF | 1.52 (0.83-2.78) | .175 | |
| 44 | 4 | PTCy | 1.88 (0.63-5.66) | .261 | |
| Donor relationship | 320 | 15 | Sibling | 1 | |
| 460 | 36 | Unrelated | 1.70 (0.93-3.10) | .083 | |
| Donor CMV serostatus | 408 | 33 | − | 1 | |
| 372 | 18 | + | 0.58 (0.33-1.03) | .065 | |
| Conditioning regimen | 379 | 26 | Nonmyeloablative/RIC | 1 | |
| 401 | 25 | Myeloablative | 0.91 (0.53-1.57) | .733 | |
| Bivariate . | . | . | . |
|---|---|---|---|
| Covariate . | Categories . | HR (95% CI) . | P . |
| CMV disease by d 100 (total events = 33) | |||
| Donor CMV serostatus | − | 1 | |
| + | 0.40 (0.19-0.86) | .019 | |
| GVHD prophylaxis | MMF/MTX | 1 | |
| PTCy | 2.39 (0.86-6.67) | .096 | |
| CMV disease by 1 y (total events = 51) | |||
| Donor CMV serostatus | − | 1 | |
| + | 0.58 (0.33-1.03) | .064 | |
| GVHD prophylaxis | MMF/MTX | 1 | |
| PTCy | 1.48 (0.53-4.13) | .452 | |
| Bivariate . | . | . | . |
|---|---|---|---|
| Covariate . | Categories . | HR (95% CI) . | P . |
| CMV disease by d 100 (total events = 33) | |||
| Donor CMV serostatus | − | 1 | |
| + | 0.40 (0.19-0.86) | .019 | |
| GVHD prophylaxis | MMF/MTX | 1 | |
| PTCy | 2.39 (0.86-6.67) | .096 | |
| CMV disease by 1 y (total events = 51) | |||
| Donor CMV serostatus | − | 1 | |
| + | 0.58 (0.33-1.03) | .064 | |
| GVHD prophylaxis | MMF/MTX | 1 | |
| PTCy | 1.48 (0.53-4.13) | .452 | |